As we hunker down for months of culture wars over abortion, here's a question worth pondering: Wouldn't it be nice if the governing party in Washington cared as much about the well-being of children and their mothers during and after birth as they do about fetuses?
The high prices for specialty drugs are forcing physicians, patients and their families to factor in financial toxicity when choosing an appropriate therapy.
The large price increases on brand name drugs and the high prices of new specialty drugs are driven by a desire for greater profits and not by the cost of research.
Regarding the story "CMS actuary predicts GOP repeal bill will reduce coverage by 13 million" (ModernHealthcare.com, June 13), with the increasing number of plans that offer horrific coverage for care (catastrophic coverage designs, for example), it is somewhat unfair to simply state a lost coverage number.
Last week's most popular healthcare stories were packed with policy news. The CMS worked through the Fourth of July week, making changes to several payment programs. Meanwhile, other providers are amping up the push for value-based care, and the Trump administration slashed another ACA program.